Indications and Evidence for Dual Antiplatelet Therapy After Acute Ischemic Stroke
| Autor: | Mackenzie Steck, Samarth P. Shah, Katleen W Chester, Jessica Ringler |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
030204 cardiovascular system & hematology Critical Care Nursing Brain Ischemia 03 medical and health sciences 0302 clinical medicine Secondary Prevention medicine Humans In patient cardiovascular diseases Intensive care medicine Acute ischemic stroke Stroke Secondary prevention Intracerebral hemorrhage Aspirin 030504 nursing business.industry Dual Anti-Platelet Therapy Guideline Clopidogrel medicine.disease Ischemic Attack Transient 0305 other medical science business Platelet Aggregation Inhibitors circulatory and respiratory physiology medicine.drug |
| Zdroj: | Critical Care Nursing Quarterly. 43:122-137 |
| ISSN: | 0887-9303 |
| DOI: | 10.1097/cnq.0000000000000298 |
| Popis: | The antiplatelet landscape for the secondary prevention of ischemic stroke has changed significantly over the past decade. Poststroke dual antiplatelet regimens are becoming increasingly routine as supported by recent literature and guideline recommendations. Dual antiplatelet therapy after stroke generally consists of aspirin and clopidogrel and is considered in the short term after stroke in select populations including those with mild stroke or transient ischemic attack and in patients with severe intracranial atherosclerosis. When initiating dual antiplatelet therapy, factors that may increase a patient's risk of bleeding must be weighed against the patient's risk of future ischemic events. This review focuses on antiplatelet medications available in the United States with the aim to provide a summary of the available literature on poststroke dual antiplatelet therapy, pharmacological nuances of the agents, and reversal of antiplatelets in the setting of intracerebral hemorrhage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|